Sedasys Post Approval Study Users Response to System Alarms

March 22, 2017 updated by: Ethicon Endo-Surgery

Open-Label Post Approval Study of the SEDASYS System User Response to System Alarms

The purpose of this study is to evaluate the users' responses to the SEDASYS® System alarms during esophagogastroduodenoscopy (EGD) or colonoscopy.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

51

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ohio
      • Toledo, Ohio, United States, 43617
        • ProMedica Toledo Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Male and female subjects 18 years or older scheduled for colonoscopy or EGD

Description

Inclusion Criteria:

  • American Society of Anesthesiologists (ASA) I and II
  • male and female
  • Scheduled for routine colonoscopy or EGD
  • ≥18 years of age
  • Able to read, speak, and understand English

Exclusion Criteria:

  • Physical or psychological condition which would impair trial participation, at the discretion of the PI
  • BMI ≥ 35
  • Pregnancy or lactation
  • Known or suspected hypersensitivity to propofol or fentanyl
  • Use of a fentanyl patch
  • Allergies to eggs, egg products soybeans or soy products
  • Diagnosis of sleep apnea
  • Gastroparesis
  • Full stomach at the time of procedure
  • Participation in any other investigational device or drug study within 30 days of enrollment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
SEDASYS System
propofol sedation with the SEDASYS System

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Percent of documented responses/actions taken in response to SEDASYS System alarms (oxygen desaturation, apnea, hypotension, and bradycardia alarms)
Time Frame: <24 hours, i.e., for duration of study procedure
<24 hours, i.e., for duration of study procedure

Secondary Outcome Measures

Outcome Measure
Time Frame
Fraction of users responses/actions to oxygen desaturation, apnea, hypotension, and/or bradycardia alarms deemed sufficient by Endpoint Adjudication Committee (EAC)
Time Frame: assessment of sufficient alarms will be reviewed by EAC after 100, 400, and 866 subjects completed the study
assessment of sufficient alarms will be reviewed by EAC after 100, 400, and 866 subjects completed the study

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: James F Martin, PhD, Ethicon Endo-Surgery, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2015

Primary Completion (Actual)

June 15, 2016

Study Completion (Actual)

June 15, 2016

Study Registration Dates

First Submitted

October 6, 2015

First Submitted That Met QC Criteria

October 9, 2015

First Posted (Estimate)

October 12, 2015

Study Record Updates

Last Update Posted (Actual)

March 24, 2017

Last Update Submitted That Met QC Criteria

March 22, 2017

Last Verified

March 1, 2017

More Information

Terms related to this study

Other Study ID Numbers

  • SED-14-001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.